Cambridge, United States
Droplet Biosciences, Inc is revolutionizing cancer care with its pioneering approach to molecular residual disease (MRD) detection through lymphatic fluid analysis. Founded in 2021, this United States-based healthcare startup is breaking new ground with its first lymph liquid biopsy. Its slogan, "Harnessing lymphatic fluid's powerful insights to improve cancer care through the first lymph liquid biopsy," encapsulates its innovative pursuit.
The company's cutting-edge, one-time MRD test leverages the high concentration of circulating tumor DNA (ctDNA) in lymphatic fluid to outperform traditional blood-based assays. This approach allows for enhanced detection of residual cancer post-surgery, significantly aiding physician decision-making regarding adjuvant treatments like radiation and chemotherapy.
Recently, Droplet Biosciences secured an $8.00M seed round on 16 March 2023, with investments from The Engine and North South Ventures. This capital infusion underscores the growing investor confidence in Droplet Biosciences as it broadens precision oncology horizons.
